Moderna stock forecast 2025-2030: Third-party predictions

Moderna (MRNA) was trading at $25.13 at 14:16 UTC, moving within an intraday range of $25.01-$25.22 (8 September 2025).

Market sentiment has been shaped by Moderna’s revised 2025 sales outlook following a UK revenue delay (Reuters, 1 August 2025). Meanwhile, a decline in US 10-year Treasury yields to 4.1% has offered some support, despite broader weakness across biotech stocks (YCharts, 5 September 2025).

Moderna share price forecast: analyst price target view

StockAnalysis (consensus snapshot)

StockAnalysis reports a 12-month average price target of $203.88 for Moderna (MRNA) as of 8 September 2025, based on coverage from 43 analysts. Figures represent a simple aggregation of sell-side targets and are updated on a rolling basis.

Investing.com (consensus page)

Investing.com lists an average 12-month target of $206.72 for Moderna as of 8 September 2025, with a high estimate of $270 and a low of $100, drawn from 65 analysts. The site presents consolidated broker targets and refreshes them as new reports are incorporated.

MarketBeat (consensus tracker)

MarketBeat shows a $207.69 average 12-month target for Moderna as of 8 September 2025, with a high of $250 and a low of $120 across 43 analysts. MarketBeat notes these are broker-published targets compiled into a consensus view.

TipRanks (ratings & targets)

TipRanks indicates a $210.73 average 12-month target for MRNA as of 8 September 2025, based on 39 analysts in the past three months; the published range extends from $100 to $250. The platform aggregates recent broker targets and updates the averages as new notes appear.

MarketWatch (LSEG/FactSet feed)

MarketWatch cites an average target price of $215.14 for Moderna as of 8 September 2025. MarketWatch attributes these consensus figures to data vendors and updates them as estimates change.

Takeaway: Across these sources, 12-month Moderna stock forecasts cluster around $204-215 on average, with highs near $250-270 and lows around $100–$120. All figures are consensus aggregates that may shift as new research becomes available.

Predictions and third-party forecasts are often inaccurate, as they cannot anticipate unforeseen market events. Past performance is not a reliable indicator of future outcomes.

MRNA stock predictions: Technical overview

Moderna (MRNA) was trading at $25.13 at 14:16 UTC on 8 September 2025, holding below its key SMA cluster, with the 20-, 50-, 100- and 200-day moving averages at approximately $26, $29, $28 and $32. The 14-day RSI stood at 41.8, suggesting neutral momentum, while the trend shows no clear directional bias.

The first resistance level to monitor is the Classic R1 at $27.18; a daily close above this could bring the $30.27 area into focus. On pullbacks, initial support lies at the Classic S1 near $22.42, while a sustained break below the 100-day moving average at around $27 could point to further downside risk. This technical analysis is provided for informational purposes only and does not constitute financial advice or a recommendation to trade.

Capital.com’s client sentiment for Moderna

Client positioning in Moderna (MRNA) CFDs shows 95.6% long positions versus 4.4% short positions, indicating a strong buy skew with buyers ahead by 82.6 percentage points (8 September 2025). This snapshot reflects open positions on Capital.com and is subject to change over time.

FAQ

Who owns the most Moderna stock?

As of September 2025, institutional investors hold the largest share of Moderna’s equity. The Vanguard Group and BlackRock are among the top institutional shareholders, each managing multi-million-share positions through index and fund holdings. Insider ownership includes company executives and early investors, but institutional free float remains larger (MarketBeat, 8 September 2025).

Is Moderna a good stock to buy?

Whether Moderna is suitable for inclusion in a portfolio depends on individual trading goals and risk tolerance. Analyst views on the Moderna stock forecast are mixed as of September 2025, with some pointing to oncology prospects while others note revenue headwinds. Traders should weigh company fundamentals against broader sector trends before making any decision.

Could Moderna stock go up or down?

The MRNA stock price can move with trial results, regulatory updates, earnings reports, and sector sentiment. Developments in new treatments or competitive pressures may influence movements either way. Current Moderna stock predictions outline both upside and downside possibilities, which can shift quickly as new information emerges.

Should I invest in Moderna stock?

Buying Moderna shares provides exposure to the biotechnology sector and the firm’s pipeline. Trading Moderna CFDs, however, allows speculation on short-term price moves without owning the shares. Contracts for difference (CFDs) are traded on margin. Leverage amplifies both your profits and your losses, making CFD trading risky. The choice depends on whether long-term exposure or shorter-term trading flexibility is preferred. Any decision should fit within an overall strategy, risk tolerance, and time horizon.